Alector licenses preclinical AL050 GCase therapy to Genentech in a deal with $100 million upfront and up to $1.17 billion in milestones.
Written By: Siddhi Bhadekar, M. Pharm (QA)
Reviewed By: Pharmacally Editorial Team
Alector, Inc. announced on October 5, 2026, that it has entered an exclusive global licensing agreement with Genentech, a member of the Roche Group, granting Genentech worldwide rights to develop and commercialize AL050, an investigational engineered glucocerebrosidase (GCase) enzyme replacement therapy (ERT) designed to reach the brain through Alector’s Brain Carrier (ABC) platform. AL050 remains in preclinical development.
Genentech to Lead AL050 Development
Under the agreement, Alector will receive a $100 million upfront payment and is eligible for up to $1.17 billion in development, regulatory and commercial milestone payments, along with tiered royalties on net sales. The individual milestone amounts and triggering events have not been disclosed. Genentech will assume responsibility for development, regulatory activities, manufacturing and commercialization of the GCase candidates across all indications.
The agreement also transfers ownership of certain existing patents specifically related to the GCase candidates to Genentech. Alector, however, retains ownership of the broader ABC platform and full rights to apply it across its wholly owned pipeline outside the GCase programs.
How AL050 Is Designed to Work
AL050 combines an Alector-engineered GCase enzyme with the company’s proprietary ABC blood-brain barrier delivery platform. The engineered enzyme was designed to improve activity and stability, while ABC is intended to facilitate transport of therapeutic molecules across the blood-brain barrier.
Once delivered to the brain, GCase is intended to break down glucosylceramide and glucosylsphingosine, substrates that can accumulate when GCase activity is impaired. Reducing this accumulation is intended to improve lysosomal function and potentially address disease biology associated with GCase dysfunction.
GCase is encoded by the GBA1 gene. Biallelic pathogenic GBA1 variants cause Gaucher disease, while GBA1 variants are an established genetic risk factor for Parkinson’s disease. Reduced GCase activity has also been associated with lysosomal dysfunction and alpha-synuclein accumulation, providing a biological rationale for restoring GCase activity in the brain.
Preclinical Evidence Supports Further Development
Alector has reported preclinical findings supporting continued development of AL050. Earlier company disclosures reported increased GCase activity in rodents and non-human primates, as well as reduced toxic substrate accumulation in a rodent GBA disease model. These findings supported the candidate’s advancement toward clinical development.
However, these findings remain preclinical. No human efficacy or safety data for AL050 have been reported.
Alector has previously targeted submission of an IND application for AL050 in 2027. Following the Genentech agreement, Genentech will be responsible for future development and regulatory activities, so the timing and execution of any IND submission will now fall under Genentech’s development program. The October 5 announcement does not establish a new IND filing date.
AL050 Represents a Distinct GCase Approach
AL050 differs from approaches that use small molecules to activate or stabilize endogenous GCase or gene therapies intended to increase GBA1 expression. Instead, it uses an engineered enzyme replacement strategy combined with a BBB delivery technology designed to enable peripheral delivery of GCase to the brain.
This approach is particularly relevant because conventional enzyme replacement therapies face challenges reaching the central nervous system due to the blood-brain barrier.
Deal Extends Alector’s Runway Into 2029
Alector said the partnership extends its cash runway into 2029, providing additional financial flexibility to advance its remaining wholly owned neurodegeneration programs. The company expects to use the resources to advance its brain-enabled anti-Aβ antibody program and tau and alpha-synuclein siRNA programs.
The transaction therefore gives Genentech responsibility for advancing AL050 while allowing Alector to retain its broader ABC platform for other therapeutic programs. For AL050, the next major milestones will depend on completion of development activities, regulatory progression and eventual clinical testing.
Reference
Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases, Alector, 05 October 2026
About the Writer
Siddhi Rajendra Bhadekar (Linkedin) is an M.Pharm professional with expertise in medical and scientific writing, literature review, publication writing, and evidence synthesis, supported by four peer-reviewed publications.
She brings working knowledge of ICH-GCP, MedDRA, pharmacovigilance, ADR/AE reporting, clinical data management, and regulatory documentation.
With experience across pharmaceutical R&D, Quality Control, and Quality Assurance, she combines scientific research skills with strong attention to accuracy and detail.
Her background in manuscript development, publication planning, and scientific communication enables her to translate complex healthcare information into clear, reliable content.